Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes

  • Shwn-Huey Shieh1, 2,
  • Janice C Probst3,
  • Fung-Chang Sung4, 5,
  • Wen-Chen Tsai1,
  • Ya-Shin Li6 and
  • Chih-Yi Chen7, 8Email author
BMC Cancer201212:174

DOI: 10.1186/1471-2407-12-174

Received: 7 October 2011

Accepted: 11 May 2012

Published: 11 May 2012

Abstract

Background

Comorbid conditions influence the survival of cancer patients. This study evaluated the influence of comorbidity on survival among lung cancer patients.

Methods

The authors evaluated the medical records of 1111 lung cancer patients of a medical center in Taiwan. Days of survival were calculated for each patient and mortality hazard ratios were estimated for associations with demographic status, comorbidity and cancer stage at diagnosis.

Results

On average, the survival time was slightly longer among women than among men (838 ± 689 vs. 749 ± 654 days, p = 0.050). Survival days increased with age (from 580 ± 526 [≤ 50 years] to 803 ± 693 [≥ 71 years] days, p = 0.020) and decreased with stage (from 1224 ± 656 [stage I] to 489 ± 536 [stage IV] days, p < 0.001). Younger patients were more likely to be diagnosed with lung cancer at a late stage. Compared with lung cancer patients without tuberculosis, those with tuberculosis had a significantly shorter average survival duration (584 vs. 791 days, p = 0.002) and a higher mortality hazard ratio (1.30, 95% CI: 1.03 - 1.65). A similar trend was observed in lung cancer patients with diabetes.

Conclusions

Lung cancer patients with comorbid tuberculosis or diabetes are at an elevated risk of mortality. These patients deserve greater attention while undergoing cancer treatment.

Keywords

Lung cancer Comorbidity Diabetes Survival Tuberculosis

Background

Cancer is a highly complicated disease. Cancer survival mainly depends on patient characteristics, the histology and pathology of the tumor, stage at diagnosis, host-tumor interaction, and comorbidities. Comorbidity has an inherent influence on each patient’s initial treatment and the treatment effectiveness of patient care. Previous studies have demonstrated that less aggressive treatment is given to patients with breast cancer, prostate cancer, lymphoma, or lung cancer who have specific existing comorbidities [16]. Several diseases such as hypertension, ischemic heart disease, cerebrovascular disease, chronic obstructive pulmonary disease (COPD), and diabetes mellitus (DM) are considered to have a significant influence on the survival of cancer patients [2, 710].

In the case of lung cancer patients, pulmonary and cardiovascular function may have a significant impact on survival [2, 1114]. Elderly patients with Stage I or II lung cancer are less likely to receive surgery than younger patients [13]. Patients with COPD, cardiovascular disease, or DM comorbidity also have a lower resection rate [13]. Janssen-Heijnen et al. reported that the morbidity and mortality of non-small cell lung cancer (NSCLC) patients following resection are associated with poor pulmonary function or cardiovascular disease [2]. Older NSCLC patients have a higher prevalence of comorbid cardiovascular disease or COPD, which may cause additional morbidity and reduce their survival. Battafarano et al. indicated that NSCLC patients with comorbidity have a two-fold increased risk of death compared with patients without comorbidity [11].

The presence of multiple comorbid diseases is common among lung cancer patients, with 22.1% of patients having five or more comorbid diseases, 54.3% having three or more, and 88.3% having one or more [1416]. Tammemagi et al. have reported that tuberculosis (TB), COPD, and DM are the most common comorbidities associated with a reduced survival among patients with lung cancer [14]. They also identified that comorbidity is important for predicting the survival of both localized and advanced lung cancer [16].

The symptoms of lung cancer can be masked by the symptoms of comorbid diseases such as chronic bronchitis, COPD, TB, DM, hypertension (HT), or even heart disease [15, 17, 18]. Patients with comorbid diseases may ignore symptoms or delay reporting them to a physician, because the symptoms of lung cancer are often confused with those of comorbid diseases. Comorbid diseases may exert direct effects on the host immune system and reduce the duration of survival, and are thus among the most important factors for determining lung cancer survival [19, 20].

The objective of this study was to investigate the influence of comorbidity on the survival of patients with lung cancer. Furthermore, we presented data showing the associations between selected comorbid diseases (TB, DM, HT, COPD, and other cancer [OC]) and survival.

Materials and methods

Sample

Data on the care of 1410 patients newly diagnosed with histologically confirmed lung cancer between October 1997 and December 2004 at a medical center in central Taiwan were extracted from the medical records of 2516 lung cancer patients by three trained medical nurses. Group I included all lung cancer patients with resectable tumors (n = 626) who had received surgery at the Department of Thoracic Surgery. Group II comprised 784 patients with late-stage lung cancer who were randomly selected from 1890 patients cared for at the Departments of Chest Medicine and Radiotherapy. There were no significant differences between the 784 randomly selected patients and those not selected in terms of age (p = 0.309) or sex (p = 0.804).

Among the 1410 patients in groups I and II, 299 were excluded from the analysis because they had incomplete baseline information (for example, missing personal ID or unknown cancer stage), metastatic cancer from other organs or postoperative deaths. The remaining 1111 patients were included in the data analysis. This study was approved by the Institutional Review Boards of the medical center.

Variable definitions

Survival

The number of days lived after the initial diagnosis was recorded. Patients’ vital status information was obtained from the official death registry. Patients were followed for more than 7 years or until deceased.

Comorbidity

Comorbidity was the disease present at the time of lung cancer diagnosis. We adopted the method developed by Charlson et al. to select comorbidities with potential association with lung cancer survival. These were OC, TB, DM, HT, and COPD [21].

Stage of the disease

The stage at diagnosis of each lung cancer case was defined in accordance with the classification outlined in the American Joint Committee on Cancer’s Cancer Staging Manual [22]. In Stage I, the cancer is in the lung only, with normal tissue around the tumor. In Stage II, the cancer has spread to nearby lymph nodes or the chest wall, diaphragm, mediastinal pleura, or parietal pericardium. In Stage III, the cancer has either spread to the lymph nodes in the mediastinum (N2; Stage IIIa) or to the lymph nodes on the opposite side of the chest or in the lower neck (N3; Stage IIIb). Stage III is locally advanced lung cancer. For the purpose of this study, patients with Stage IIIa or IIIb lung cancer are combined into a single group. In Stage IV, the cancer has spread to other parts of the body or to another lobe of the lungs. A physician checked the pathology or cytology reports and the clinical image studies to confirm the tumor stage diagnosis.

Control variables

Patients’ demographic characteristics (age, sex, religion, education, marital status, and occupation) with implications for survival were controlled for in the multivariate analyses.

Data analysis

Data analyses first used descriptive statistical analyses to identify the mean, median and interquartile ranges of survival duration by sociodemographic status, comorbidity and cancer stage at diagnosis. Survival duration was compared between men and women, among age groups (≤ 50, 51–60, 61–70 and ≥ 71 years), other demographic variables, among patients with and without the selected comorbidity (OC, TB, COPD, DM and HT), and among lung cancer stages. Mean days of survival were also estimated to evaluate the interactions between comorbidities and cancer stages. Multivariate Cox proportional hazards regression was used to compute the adjusted lung cancer mortality hazard ratios (HR) and 95% confidence intervals (CI). Lung cancer mortality HRs were calculated separately for men and women, different age groups, patients with or without a specific comorbidity and different cancer stages. We also used a Kaplan–Meier model to compare patient survival rates between those with and without a comorbidity that was significantly associated with the duration of survival. Analyses were performed using the SAS Statistics System (Version 9.1, SAS Institute Inc., Cary, NC).

Results

Comparison of survival duration

The patients included in the analysis were mostly male, elderly, and married. Most patients had a low educational attainment and a high proportion of religious affiliation (Table 1). Overall, the mean survival duration was 772 ± 665 days, with a median of 624 days and interquartile range of 205–1190 days. Survival medians were consistently lower than survival means for all investigated variables. Survival duration was longer in women than in men, and increased with age, with mean from 580 ± 526 days for ≤ 50 years group to 803 ± 693 days for ≥ 71 years group (p = 0.020). Survival duration was not significantly associated with education level, religion or job status. Table 1 also shows that almost half the patients had at least one comorbid disease at baseline. The most prevalent comorbidity was HT (26.2%), followed by DM (11.7%), TB (9.7%), OC (5.8%) and COPD (5.0%). On average, patients with comorbid OC or COPD had a longer duration of survival, but this was not a statistically significant difference. Those with comorbid tuberculosis (p = 0.002), diabetes (p = 0.001) or hypertension (p = 0.178) had a shorter duration of survival. Patient survival duration decreased with advancing cancer stage, from an average of 1224 days for those diagnosed with stage I to 489 days for those diagnosed with stage IV cancer.
Table 1

Means, medians and interquartile ranges of survival days in patients with lung cancer by patient characteristics, co-morbidity and stage of disease

Criteria

N = 1111

Survival Days

P-value for means

n

%

Median

25th - 75th

Mean ± SD

Overall

1111

(100)

624

205 - 1190

772 ± 665

 

Age

      

 ≤ 50

94

(8.5)

419

188 - 864

580 ± 526

0.020

 51 - 60

155

(14.0)

597

234 - 1039

738 ± 641

 

 61 - 70

290

(26.1)

699

244 - 1228

792 ± 651

 

 ≥ 71

572

(51.5)

654

187 - 1268

803 ± 693

 

Gender

      

 Male

822

(74.0)

596

188 - 1152

749 ± 654

0.050

 Female

289

(26.0)

711

259 - 1279

838 ± 689

 

Marital Status

      

 Married

964

(88.1)

626

216 - 1200

780 ± 666

0.112

 Single (included divorce)

130

(11.9)

529

123 - 971

682 ± 636

 

Education

      

 < Junior high

654

(63.3)

556

185 - 1187

756 ± 681

0.397

 Junior high

137

(13.3)

647

211 - 1163

751 ± 611

 

 Senior high

171

(16.6)

697

271 - 1287

842 ± 681

 

 ≥ College

71

(6.9)

528

201 - 1115

707 ± 623

 

Religion

      

 No

294

(28.0)

651

182 - 1163

763 ± 662

0.847

 Yes

755

(72.0)

615

211 - 1193

772 ± 666

 

Occupation

      

 Work

323

(30.0)

554

188 - 1122

744 ± 662

0.378

 Retired

296

(27.5)

555

177 - 1170

743 ± 672

 

 Not work

457

(42.5)

715

233 - 1202

801 ± 654

 

Comorbidity

      

Other cancer

      

 No

1031

(94.2)

606

201 - 1180

764 ± 666

0.116

 Yes

64

(5.8)

813

350 - 1376

898 ± 643

 

Tuberculosis

      

 No

989

(90.3)

653

220 - 1206

791 ± 667

0.002

 Yes

106

(9.7)

364

107 - 856

584 ± 612

 

COPD

      

 No

1040

(95.0)

614

206 - 1176

765 ± 662

0.162

 Yes

55

(5.0)

863

317 - 1353

894 ± 714

 

Diabetes

      

 No

967

(88.3)

651

220 - 1220

794 ± 670

0.001

 Yes

128

(11.7)

427

134 - 929

600 ± 601

 

Hypertension

      

 No

808

(73.8)

654

220 - 1219

788 ± 660

0.178

 Yes

287

(26.2)

>546

169 - 1122

726 ± 677

 

Stage

      

 I

216

(19.4)

1164

743 - 1681

1224 ± 656

<0.001

 II

106

(9.5)

913

546 - 1498

1045 ± 674

 

 III

406

(36.5)

555

220 - 1073

727 ± 622

 

 IV

383

(34.5)

273

94 - 723

489 ± 536

 

COPD: chronic obstructive pulmonary disease.

Survival duration by comorbidity and cancer stage

Table 2 shows the mean survival duration for lung cancer patients by comorbidity and cancer stage. In general, the mean survival duration decreased with advancing cancer stage. Patients with a comorbidity tended to have a shorter survival duration, except for those with comorbid COPD or HT who were diagnosed with lung cancer at an early stage. On average, patients with comorbid TB or DM had a shorter survival duration than patients without the corresponding diseases among all stages. The Kaplan–Meier analysis showed that 7-year survival rates were 11% lower for patients with TB than for patients without TB (10% vs. 21%) (Figure 1) and 7% less for patients with DM than for patients without DM (14% vs. 21%) (Figure 2).
Table 2

Baseline prevalence of comorbidity among lung cancer patients and mean survival days by comorbidity and stage of lung cancer at diagnosis

Comorbidity

Stage

P-value

I

II

III

IV

N = 214

N = 104

N = 399

N = 378

 

%

Mean

%

Mean

%

Mean

%

Mean

 

Other cancer

         

 No

91.6

1235

96.2

1072

94.7

718

94.4

467

-

 Yes

8.4

1157

3.8

334

5.3

829

5.6

853

0.093

Tuberculosis

         

 No

92.5

1247

89.4

1075

90.2

743

89.4

500

-

 Yes

7.5

1002

10.6

774

9.8

553

10.6

395

0.004

COPD

         

 No

92.1

1213

94.2

1038

95.5

726

96.3

491

-

 Yes

7.9

1408

5.8

1123

4.5

685

3.7

435

<0.001

Diabetes

         

 No

86.9

1280

90.4

1065

88.7

752

88.1

492

-

 Yes

13.1

889

9.6

836

11.3

503

11.9

466

0.008

Hypertension

         

 No

70.1

1209

77.9

1111

75.4

757

73.0

498

-

 Yes

29.9

1275

22.1

806

24.6

622

27.0

465

<0.001

Mean: Average of survival days.

COPD: chronic obstructive pulmonary disease.

Missing data: 16 cases.

https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-12-174/MediaObjects/12885_2011_Article_3195_Fig1_HTML.jpg
Figure 1

The comparison of survival time between lung cancer patient with or without TB.

https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-12-174/MediaObjects/12885_2011_Article_3195_Fig2_HTML.jpg
Figure 2

The comparison of survival time between lung cancer patient with or without DM.

Mortality hazard ratio

The results of the multivariate Cox proportional hazards analysis shows that men were at higher risk of death than women (HR = 1.44, 95% CI = 1.20–1.72, Table 3). The HRs were not significantly different among age groups. Patients with comorbid TB had a HR of 1.30 (95% CI = 1.03–1.65). Those with comorbid DM also had a higher risk of death (HR = 1.44, 95% CI = 1.15–1.80) during the observation period. Patients with comorbid OC, COPD or HT did not have a higher risk of death than patients without the corresponding comorbidity. The adjusted analysis showed that the stage at diagnosis had a significant association with survival. Using Stage I as the reference, the risk of death was markedly higher among patients diagnosed at advanced cancer stages (Stage II: HR =1.85, 95% CI = 1.30–2.61; Stage III: HR = 3.35, 95% CI = 2.57–4.35; Stage IV: HR = 5.63, 95% CI = 4.32–7.33).
Table 3

Mortality rate and multivariable Cox proportional hazards regression model measured hazard ratio (HR) and 95% confidence interval (CI) of mortality by demographic status, co-morbidity and stage of lung cancer

Variables

N

Death

Person-days

Mortality rate

Rate ratio (95%CI)

HRs* (95% CI)

p-value

Overall

1111

738

857762

0.86

     

Gender

         

 Male

822

565

615638

0.92

1.28

(1.08-1.52)

1.44

(1.20-1.72)

<0.001

 Female

289

173

242124

0.71

1.00

 

1.00

  

Age, years

         

 ≤ 50

94

68

54514

1.25

1.47

(1.14-1.90)

1.29

(0.99-1.70)

0.064

 51 - 60

155

98

114428

0.86

1.01

(0.81-1.26)

0.89

(0.71-1.12)

0.328

 61 - 70

290

183

229726

0.80

0.94

(0.79-1.12)

1.00

(0.83-1.20)

0.994

 ≥ 71

572

389

459094

0.85

1.00

 

1.00

  

Comorbidity

         

Other Cancer

         

 No

1031

690

787641

0.88

1.00

 

1.00

  

 Yes

64

38

57496

0.66

0.75

(0.54-1.05)

0.77

(0.55-1.07)

0.124

Tuberculosis

         

 No

989

649

783186

0.83

1.00

 

1.00

  

 Yes

106

79

61951

1.28

1.54

(1.22-1.94)

1.30

(1.03-1.65)

0.030

COPD

         

 No

1040

696

795978

0.87

1.00

 

1.00

  

 Yes

55

32

49159

0.65

0.74

(0.52-1.06)

0.97

(0.67-1.38)

0.848

Diabetes

         

 No

967

633

768281

0.82

1.00

 

1.00

  

 Yes

128

95

76856

1.24

1.50

(1.21-1.86)

1.44

(1.15-1.80)

0.002

Hypertension

         

 No

808

534

636661

0.84

1.00

 

1.00

  

 Yes

287

194

208476

0.93

1.11

(0.94-1.31)

1.07

(0.90-1.27)

0.453

Stage

         

 I

216

73

264485

0.28

1.00

 

1.00

  

 II

106

60

110785

0.54

1.96

(1.39-2.76)

1.85

(1.30-2.61)

0.001

 III

406

289

295328

0.98

3.55

(2.74-4.58)

3.35

(2.57-4.35)

<0.001

 IV

383

316

187164

1.69

6.12

(4.74-7.89)

5.63

(4.32-7.33)

<0.001

p for trend

      

<0.001

 

COPD: chronic obstructive pulmonary disease.

* Adjusted Hazard Ratios, obtained with statistical adjustment for all the variables listed in this table.

Discussion

This study examined how patient characteristics and selected comorbidities are associated with survival for patients with lung cancer. Patients with comorbid TB or DM had a reduced duration of survival, and a higher mortality hazard. Younger patients had a shorter survival duration than older patients, a phenomenon has not been previously reported.

Previous studies have shown that patient demographic characteristics such as age, sex, marital status, and education are important factors associated with cancer survival [13, 17, 2326]. We found sex to be significantly associated with survival in the multivariate analysis (Table 3). Men had a shorter survival duration than women and an approximately 44% increased mortality hazard. This result is consistent with other studies [16, 27, 28]. It is generally recognized that lung cancer survival among women is far better than that among men [27, 28]. Lung cancer is biologically different in men and women. The biological characteristics and prognostic profiles of the tumor may also differ between them [2628]. Approximately only 4.0–9.0% of women are smokers in Taiwan. Female patients are more likely to have never smoked than male patients [29, 30]. Taiwanese women are also more likely than men to present with adenocarcinoma rather than squamous carcinoma of the lung [31].

Education, religion, marital status, and occupation were not found to be significantly related to survival in the adjusted analysis. Several previous studies have found a significant association between age and survival [13, 23, 24, 26]. We found that younger patients had a shorter survival in both the crude and adjusted analyses. A further analysis using a contingency table of age by stage showed that a greater proportion of younger patients (≤ 50 years) than older patients had their lung cancer diagnosed at a late stage (47.9% vs. 30.1% in stage IV) (data not shown). This late detection is likely to explain why the younger patients had a much shorter survival duration than the oldest group of patients (580 ± 526 vs. 803 ± 693 days on average). Young patients are apparently unaware of the importance of early detection. They are also more likely to be heavy smokers [16, 32].

The lung cancer survival duration was also found to be determined by the stage of disease, tumor biology and comorbidity. Comorbidity is not only an independent prognostic factor for surgical resection, but also important in host-resistance and host–tumor interaction, and has a significant role in survival [2, 1113, 19].

Only a few studies have investigated the association between comorbidity and lung cancer survival. Tammemagi et al. and Battafarano et al. found support for the hypothesis that comorbidity is inversely related to survival duration [11, 14]. Several studies found that TB, DM, OC, COPD and peripheral vascular disease may independently predict reduced survival duration [9, 14]. Our study also found that lung cancer patients with comorbid TB or DM have a shorter survival duration across all stages of lung cancer. However, some other studies have contradictory findings. Janssen-Heijnen et al. reported that comorbidity was not a significant factor determining cancer survival [13]. Poorer survival among patients with TB or DM, even with stage at initial diagnosis held constant, may stem from less efficient immunization, anti-tumor defense systems, and multiple organ dysfunctions with these conditions. Poorer lung function, physical performance status, and nutrition, as well as lower immunization among lung cancer patients with TB may influence the available treatment choices [19, 20]. Furthermore, the chronic cough caused by TB may cause patients to be ignorant their lung cancer and delay them from seeking medical treatment, thus influencing their survival.

The current clinical evaluation of treatment effectiveness and the care of lung cancer patients put more emphasis on cancer stage and tumor biology, while ignoring other patient characteristics. Comorbidities may influence the choice of treatment and treatment side effects, which are associated with patient survival. Therefore, physicians should carefully evaluate each patient’s comorbidities. In the present study, 9.7% of the lung cancer patients had TB. TB patients are at higher risk of developing lung cancer. Yu et al. found that patients with pulmonary TB are at 11-fold higher risk of developing lung cancers than those without TB [33]. Therefore, it is necessary to examine the respiratory tract symptoms of patients with TB to screen for lung cancer and improve their survival. DM is one of the world’s major chronic diseases and leading causes of death. DM patients have poor nutrition absorption, and are at risk of higher glucose and immunization, which may also lead to limited treatment choices and reduced survival [2, 710].

Conclusions

In conclusion, this study suggests that lung cancer patients with comorbidity, particularly DM or TB deserve more attention while undergoing cancer treatment. In addition, having a valid disease-specific instrument to measure and classify the overall severity of comorbidity is very important for improving the outcome of lung cancer care, especially for long-term survival. This study also observed shorter survival durations among young patients. More attention should be devoted to these patients, who may have had the disease diagnosed at a late stage.

Our findings reflect the importance of public health in reducing the prevalence of comorbidities and late diagnosis among lung cancer patients. However, the biological and/or appropriate therapeutic implications of comorbidities for lung cancer have not been addressed in this study. They remain important issues for future study. Further investigations focusing on caring for lung cancer patients with comorbid diseases such as TB or DM are needed to provide direction for clinicians treating patients with comorbid conditions.

Conflicting interests

There are no potential conflicts of interest for any of the authors. All authors have no reportable conflicts.

Declarations

Acknowledgements

The authors would like to thank Dr. Jiun-Yi Hsia for his assistance in the provision of professional input throughout the course of this study. This study was supported in part by Department of Health Cancer Research Cancer of Excellence, Taiwan (DOH100-TD-C111-005), Clinical Trial and Research Center of Excellence (DOH100-TD-B111-004), and China Medical University Hospital (1MS1).

Authors’ Affiliations

(1)
Department of Health Services Administration, China Medical University
(2)
Department of Nursing, China Medical University Hospital
(3)
Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina
(4)
Department of Public Health, China Medical University
(5)
Department of Medical Research, China Medical University Hospital
(6)
Department of Health Systems Management, Chung-Shan Medical University and Hospital
(7)
Department of Respiratory Therapy, China Medical University
(8)
Cancer center, China Medical University Hospital

References

  1. Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD: Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008, 26 (1): 54-59. 10.1200/JCO.2007.12.8322.View ArticleGoogle Scholar
  2. Janssen-Heijnen ML, Maas HA, Houterman S, Lemmens VE, Rutten HJ, Coebergh JW: Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer. 2007, 43 (15): 2179-2193. 10.1016/j.ejca.2007.06.008.View ArticlePubMedGoogle Scholar
  3. Lash TL, Thwin SS, Horton NJ, Guadagnoli E, Silliman RA: Multiple informants: a new method to assess breast cancer patients' comorbidity. Am J Epidemiol. 2003, 157 (3): 249-257. 10.1093/aje/kwf193.View ArticlePubMedGoogle Scholar
  4. Ludbrook JJ, Truong PT, MacNeil MV, Lesperance M, Webber A, Joe H, Martins H, Lim J: Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. Int J Radiat Oncol Biol Phys. 2003, 55 (5): 1321-1330. 10.1016/S0360-3016(02)04576-5.View ArticlePubMedGoogle Scholar
  5. Post PN, Kil PJ, Hendrikx AJ, Janssen-Heijnen ML, Crommelin MA, Coebergh JW: Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int. 1999, 84 (6): 652-656.View ArticlePubMedGoogle Scholar
  6. Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994, 120 (2): 104-110.View ArticlePubMedGoogle Scholar
  7. Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW: Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer. 1998, 21 (2): 105-113. 10.1016/S0169-5002(98)00039-7.View ArticlePubMedGoogle Scholar
  8. Ogle KS, Swanson GM, Woods N, Azzouz F: Cancer and comorbidity: redefining chronic diseases. Cancer. 2000, 88 (3): 653-663. 10.1002/(SICI)1097-0142(20000201)88:3<653::AID-CNCR24>3.0.CO;2-1.View ArticlePubMedGoogle Scholar
  9. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, et al: Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011, 364 (9): 829-841.View ArticlePubMedGoogle Scholar
  10. van Spronsen DJ, Janssen-Heijnen ML, Breed WP, Coebergh JW: Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol. 1999, 78 (7): 315-319. 10.1007/s002770050521.View ArticlePubMedGoogle Scholar
  11. Battafarano RJ, Piccirillo JF, Meyers BF, Hsu HS, Guthrie TJ, Cooper JD, Patterson GA: Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2002, 123 (2): 280-287. 10.1067/mtc.2002.119338.View ArticlePubMedGoogle Scholar
  12. Budisin E: Comorbidity in Lung Cancer – Operated Patients, Impact on Survival and Prognosis. 2006, Evica Budisin, Washington, DC, USAGoogle Scholar
  13. Janssen-Heijnen ML, Smulders S, Lemmens VE, Smeenk FW, van Geffen HJ, Coebergh JW: Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax. 2004, 59 (7): 602-607. 10.1136/thx.2003.018044.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P: Impact of comorbidity on lung cancer survival. International journal of cancer Journal international du cancer. 2003, 103 (6): 792-802.View ArticlePubMedGoogle Scholar
  15. Koyi H, Hillerdal G, Branden E: Patient's and doctors' delays in the diagnosis of chest tumors. Lung Cancer. 2002, 35 (1): 53-57. 10.1016/S0169-5002(01)00293-8.View ArticlePubMedGoogle Scholar
  16. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P: Smoking and lung cancer survival: the role of comorbidity and treatment. Chest. 2004, 125 (1): 27-37. 10.1378/chest.125.1.27.View ArticlePubMedGoogle Scholar
  17. Hsu NY, Chen CY, Chung KP, Hsu CP, Hsia JY PYW: Pulmonary tuberculosis and lung cancer. Chin Med J. 1996, 57 (6): S140-Google Scholar
  18. Piccirillo JF: Importance of comorbidity in head and neck cancer. Laryngoscope. 2000, 110 (4): 593-602. 10.1097/00005537-200004000-00011.View ArticlePubMedGoogle Scholar
  19. Bergman L, Dekker G, van Kerkhoff EH, Peterse HL, van Dongen JA, van Leeuwen FE: Influence of age and comorbidity on treatment choice and survival in elderly patients with breast cancer. Breast cancer research and treatment. 1991, 18 (3): 189-198. 10.1007/BF01990035.View ArticlePubMedGoogle Scholar
  20. Firat S, Bousamra M, Gore E, Byhardt RW: Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002, 52 (4): 1047-1057. 10.1016/S0360-3016(01)02741-9.View ArticlePubMedGoogle Scholar
  21. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases. 1987, 40 (5): 373-383. 10.1016/0021-9681(87)90171-8.View ArticlePubMedGoogle Scholar
  22. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, Sullivan BO, Sobin LH, JW Y: AJCC Cancer Staging Manual (5th ed.). 1997, Lippincott-Raven Publishers, PhiladelphiaGoogle Scholar
  23. Bibb SC: The relationship between access and stage at diagnosis of breast cancer in African American and Caucasian women. Oncology nursing forum. 2001, 28 (4): 711-719.PubMedGoogle Scholar
  24. Caplan LS, Helzlsouer KJ, Shapiro S, Freedman LS, Coates RJ, Edwards BK: System delay in breast cancer in whites and blacks. Am J Epidemiol. 1995, 142 (8): 804-812.PubMedGoogle Scholar
  25. Dayal HH, Power RN, Chiu C: Race and socio-economic status in survival from breast cancer. Journal of chronic diseases. 1982, 35 (8): 675-683. 10.1016/0021-9681(82)90020-0.View ArticlePubMedGoogle Scholar
  26. Porta M, Gallen M, Malats N, Planas J: Influence of "diagnostic delay" upon cancer survival: an analysis of five tumour sites. Journal of epidemiology and community health. 1991, 45 (3): 225-230. 10.1136/jech.45.3.225.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Moore KA, Mery CM, Jaklitsch MT, Estocin AP, Bueno R, Swanson SJ, Sugarbaker DJ, Lukanich JM: Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer. Ann Thorac Surg. 2003, 76 (6): 1789-1795. 10.1016/S0003-4975(03)01024-5.View ArticlePubMedGoogle Scholar
  28. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P: In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. Journal of clinical epidemiology. 2004, 57 (6): 597-609. 10.1016/j.jclinepi.2003.11.002.View ArticlePubMedGoogle Scholar
  29. Bureau of Tobacco and Alcohol Monopoly: Annual Report of Tobacco, Alcohol Consumption Investigation in Taiwan Area. 1993, Taiwan Provincial Government, TaipeiGoogle Scholar
  30. Ko YC, Lee CH, Chen MJ, Huang CC, Chang WY, Lin HJ, Wang HZ, Chang PY: Risk factors for primary lung cancer among non-smoking women in Taiwan. International journal of epidemiology. 1997, 26 (1): 24-31. 10.1093/ije/26.1.24.View ArticlePubMedGoogle Scholar
  31. Bureau of Health Promotion: Cancer Registry Annual Report, 2008. 2010, Department of Health, The Executive Yuan, Taipei, TaiwanGoogle Scholar
  32. Bureau of Health Promotion: Interactive Health Data Querying System. In. R.O.C. 2011, Department of Health, TaiwanGoogle Scholar
  33. Yu YH, Liao CC, Hsu WH, Chen HJ, Liao WC, Muo CH, Sung FC, Chen CY: Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2011, 6 (1): 32-37. 10.1097/JTO.0b013e3181fb4fcc.View ArticleGoogle Scholar
  34. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/174/prepub

Copyright

© Shieh et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.